

Pharmacogenomics Gene/Drug-Pair Decision Flow Chart: VKORC1-Warfarin 2017

Warfarin

<i>VKORC1</i> Genotype (-1639G>A, rs9923231)	*1/*1	*1/*2	*1/*3	*1/*5	*1/*6	*1/*8	*1/*11	*2/*2	*2/*3	*2/*5	*2/*6	*2/*8	*2/*11
GG	WAREM	WAREM	WARIM	WARIM	WARIM	WAREM	WAREM	WARIM	WARIM	WARIM	WARIM	WARIM	WARIM
GA	WAREM	WARIM	WARIM	WARIM	WARIM	WARIM	WARIM	WARIM	WARPM	WARPM	WARPM	WARIM	WARIM
AA	WARIM	WARIM	WARPM	WARPM	WARPM	WARIM	WARIM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM


<i>VKORC1</i> Genotype (-1639G>A, rs9923231)	*3/*6	*3/*8	*3/*11	*5/*5	*5/*6	*5/*8	*5/*11	*6/*6	*6/*8	*6/*11	*8/*8	*8/*11	*11/*11
GG	WARPM	WARIM	WARIM	WARPM	WARPM	WARIM	WARIM	WARPM	WARIM	WARIM	WARIM	WARIM	WARIM
GA	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARIM	WARIM	WARIM
AA	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM	WARPM

INTERPRETATION:

These genotyping results predict that this individual has a normal genetic phenotype and is likely to respond to standard dose of warfarin. However, their dose may need to be modified by other clinical factors (e.g., age, weight, concurrent medications, and liver disease). Standard INR monitoring is still required.

Calculating a warfarin dose based on genotype and other clinical findings is available (e.g., www.warfarindosing.org).

It is possible that this individual has a rare variant in the *CYP2C9*, *VKORC1*, or *CYP4F2* genes that are not examined by this assay.



***Classification of Recommendation:**

- Based on the strength of the literature base:
- Strong, moderate, or weak.

(*5 & *6 are ≈ *3)
*8, *11 are decreased function of unknown magnitude